(93) elucidated the combined effects of the clinically used angiotensin I converting enzyme (ACE) inhibitor perindopril (PE) and IFN-β on HCC development and angiogenesis in mice. This evidence concerns the gene IFNB1 and hepatocellular carcinoma.